# US 2024/0189250 A1 · Aqueous wound healing formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189250 A1
- Document ID: US20240189250A1
- Status: Published application
- Kind: A1
- Application number: 18/533,558
- Filed: 2023-12-08
- Published: 2024-06-13
- Earliest claimed: 2021-08-20
- Assignees: Advantice Health, LLC
- Applicants: Advantice Health, LLC
- Inventors: Hellen SPANJER; Kathryn Jill RIVERA; Stephen MAIDA; Joseph LIBRIZZI; Anthony D'OVIDIO
- Web page: https://patentgrep.com/patent/US20240189250A1

## CPC

- A61K 9/7015: {Drug-containing film-forming compositions, e.g. spray-on}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/055: the aromatic ring being substituted by halogen
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/288: Taraxacum (dandelion)
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61K 36/886: Aloeaceae (Aloe family), e.g. aloe vera
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 26/0052: {Mixtures of macromolecular compounds}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/0076: {Sprayable compositions}
- A61L 26/008: {Hydrogels or hydrocolloids}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a water resistant wound cover with high comfort and good air permeability. In particular, the present invention relates to an aqueous wound healing formulation comprising a water-soluble or a water-dispersible polymeric material that does not sting when applied to a minor injury to the skin.

## Claims

### Claim 1

(canceled)

### Claim 2

An aqueous wound healing formulation comprising:
(i) a water-soluble or a water-dispersible polymeric material comprising:
a first polymer comprising a polyvinyl ester polymer, and
a second polymer comprising an acrylate copolymer;
(ii) optionally, one or more thickening agents;
(iii) optionally, one or more preservative agents; and
(iv) optionally, one or more colouring agents.

### Claim 3 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said polyvinyl ester polymer is selected from the group consisting of polyvinyl acetate (PVAc), polyvinyl benzoate, polyvinyl butyrate, polyvinyl formate, polyvinyl propionate, and polyvinyl stearate.

### Claim 4 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein the first polymer comprises polyvinyl acetate.

### Claim 5 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein the amount of the first polymer is in the range of about 5 wt % to about 20 wt % with respect to the total weight of said aqueous formulation.

### Claim 6 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said acrylate copolymer comprises styrene or a derivative thereof.

### Claim 7 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said acrylate copolymer is a styrene/acrylate copolymer.

### Claim 8 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein the weight ratio between the first polymer and second polymer is in the range of about 3.2:1 to about 1:1.

### Claim 9 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said acrylate copolymer is a copolymer of allyl methacrylate and one or more monomers consisting of acrylic acid and/or methacrylic acid.

### Claim 10 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said acrylate copolymer is a copolymer of allyl methacrylate and an aminomethyl propanol salt of a monomer consisting of acrylic acid and/or methacrylic acid (AMP-acrylate).

### Claim 11 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein the weight ratio between the first polymer and second polymer is in the range of about 8:1 to about 1:1.

### Claim 12 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said aqueous formulation does not comprise any cyanoacrylate polymers.

### Claim 13 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said aqueous formulation comprises:
one or more thickening agents;
one or more preservative agents; and/or
one or more colouring agents.

### Claim 14 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said one or more thickening agents are present and selected from the group consisting of cellulosics, gums, saccharides, proteins, organosilicones, and fumed silica, and combinations thereof.

### Claim 15 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said aqueous formulation further comprises one or more additives selected from the group consisting of antiseptic agents, local anaesthetic agents, anti-inflammatory agents, antihistamines, botanical ingredients, and combinations thereof.

### Claim 16 (depends on 15)

The aqueous wound healing formulation according to claim 15, wherein said one or more antiseptic agents are selected from the group consisting of benzethonium chloride, chlorhexidine, chloroxylenol, isopropyl alcohol, hexachlorophene, benzalkonium chloride, and hydrogen peroxide, and combinations thereof.

### Claim 17 (depends on 15)

The aqueous wound healing formulation according to claim 15, wherein said one or more local anaesthetic agents are selected from the group consisting of lidocaine, benzocaine, butamben, dibucaine, oxybuprocaine, pramoxine, proxymetacaine, and tetracaine, and combinations thereof.

### Claim 18 (depends on 2)

The aqueous wound healing formulation according to claim 2, wherein said aqueous formulation is substantially free of organic solvents.

### Claim 19 (depends on 2)

A container comprising an aqueous wound healing formulation according to claim 2, wherein the container is of a type selected from the group consisting of bottles, spray packs, daubers and droppers.

### Claim 20 (depends on 19)

The container according to claim 19, wherein the container is a bottle comprising a lid comprising an applicator brush.

### Claim 21 (depends on 2)

A kit-of-parts comprising:
(i) an aqueous wound healing formulation according to claim 2 and optionally a means for applying the aqueous wound healing formulation to the skin; or
(ii) a container comprising the aqueous wound healing formulation, wherein the container is of a type selected from the group consisting of bottles, spray packs, daubers and droppers; and
(iii) instructions for use.
